ATE473013T1 - Induzierte immunantwort gegen den katzen- immunschwäche-virus - Google Patents

Induzierte immunantwort gegen den katzen- immunschwäche-virus

Info

Publication number
ATE473013T1
ATE473013T1 AT02740841T AT02740841T ATE473013T1 AT E473013 T1 ATE473013 T1 AT E473013T1 AT 02740841 T AT02740841 T AT 02740841T AT 02740841 T AT02740841 T AT 02740841T AT E473013 T1 ATE473013 T1 AT E473013T1
Authority
AT
Austria
Prior art keywords
gag
fiv
response against
feline
vaccine
Prior art date
Application number
AT02740841T
Other languages
English (en)
Inventor
Laurent Fischer
Original Assignee
Merial Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Sas filed Critical Merial Sas
Application granted granted Critical
Publication of ATE473013T1 publication Critical patent/ATE473013T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT02740841T 2001-06-01 2002-05-29 Induzierte immunantwort gegen den katzen- immunschwäche-virus ATE473013T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0107275A FR2825280B1 (fr) 2001-06-01 2001-06-01 Vaccination contre le virus de l'immunodeficience feline
PCT/FR2002/001809 WO2002096349A2 (fr) 2001-06-01 2002-05-29 Vaccination contre le virus de l'immunodeficience feline

Publications (1)

Publication Number Publication Date
ATE473013T1 true ATE473013T1 (de) 2010-07-15

Family

ID=8863923

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02740841T ATE473013T1 (de) 2001-06-01 2002-05-29 Induzierte immunantwort gegen den katzen- immunschwäche-virus

Country Status (14)

Country Link
EP (1) EP1418941B9 (de)
JP (1) JP2004535406A (de)
AT (1) ATE473013T1 (de)
AU (1) AU2002314274B2 (de)
BR (1) BRPI0210229B1 (de)
CA (1) CA2448620C (de)
CZ (1) CZ305257B6 (de)
DE (1) DE60236943D1 (de)
DK (1) DK1418941T3 (de)
ES (1) ES2348226T3 (de)
FR (1) FR2825280B1 (de)
PL (1) PL210450B1 (de)
PT (1) PT1418941E (de)
WO (1) WO2002096349A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06005424A (es) 2003-11-13 2007-01-25 Univ Georgia Res Found Metodos para caracterizar virus de enfermedad bursal infecciosa.
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
AU2014312123A1 (en) 2013-08-29 2016-03-17 Temple University Of The Commonwealth System Of Higher Education Methods and compositions for RNA-guided treatment of HIV infection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833993A (en) * 1994-04-29 1998-11-10 Pharmacia & Upjohn Company Feline immunodeficiency virus vaccine
US7255862B1 (en) * 1996-11-14 2007-08-14 Connaught Technology Corporation ALVAC/FIV constructs
BR0011732B1 (pt) * 1999-06-10 2014-02-04 Vacinas de dna para animais de companhia e de esporte
EP1074625A3 (de) * 1999-06-14 2002-01-02 Pfizer Products Inc. DNS impfstoff gegen das immunschwächevirus der Katze

Also Published As

Publication number Publication date
DK1418941T3 (da) 2010-11-01
BRPI0210229B1 (pt) 2016-11-22
JP2004535406A (ja) 2004-11-25
WO2002096349A2 (fr) 2002-12-05
EP1418941B1 (de) 2010-07-07
EP1418941A2 (de) 2004-05-19
ES2348226T3 (es) 2010-12-01
WO2002096349A3 (fr) 2004-03-11
CA2448620C (en) 2013-05-28
PL210450B1 (pl) 2012-01-31
EP1418941B9 (de) 2010-10-20
CZ20033229A3 (cs) 2004-03-17
AU2002314274B2 (en) 2008-03-20
DE60236943D1 (de) 2010-08-19
PL365742A1 (en) 2005-01-10
CZ305257B6 (cs) 2015-07-08
CA2448620A1 (en) 2002-12-05
FR2825280A1 (fr) 2002-12-06
BR0210229A (pt) 2004-07-20
FR2825280B1 (fr) 2005-04-15
PT1418941E (pt) 2010-10-12

Similar Documents

Publication Publication Date Title
ATE526411T1 (de) Avirulente, immunogene flavivirus-chimäre
ATE334216T1 (de) Impstoff gegen felines immunodefizienz-virus
DE60110822D1 (de) Zubereitung zur immunisierung gegen den aids-virus
EA200700849A1 (ru) Первичная/бустерная противомалярийная вакцина
EP2345665A3 (de) Impfstoff aus der NS1-Untereinheit eines Flavivirus
AR003425A1 (es) Poxvirus recombinante de mapache, vacuna para uso en gatos y uso de poxvirus para preparar una vacuna util para evitar o para disminuir la enfermedad causada por el virus de inmunodeficiencia felina (fiv)
CY1107818T1 (el) Hiv-1 tat, ή παραγωγα αυτου για προφυλακτικο και θεραπευτικο εμβολιασμο
HUP9900389A2 (hu) Rekombináns vaccinia vektorok keverékét tartalmazó HIV elleni polienv vakcinák
NO992369D0 (no) Poxvirusbaserte ekspresjonsvektorer inneholdende heterologe innslag avledet fra lentivirus
AU2003228962A8 (en) Ferritin fusion proteins for use in vaccines and other applications
BR0206823A (pt) Gene quimérico, proteìna quimérica, vìrus recombinante, composição de vacina, uso de uma composição de vacina, combinação terapêutica ou preventiva, e, plasmìdeo
TW377373B (en) Recombinant raccoon pox viruses and their use as an effective vaccine against feline infectious peritonitis virus disease
WO2005035558A3 (en) Piscirickettsia salmonis antigens and use thereof
DE50010240D1 (de) Impfstoff gegen infektionen mit lentiviren, wie dem felinen immunschwäche-virus der katze
AR047581A1 (es) Vacunas de calicivirus felino
MX2022007217A (es) Vacuna epitópica para virus de fiebre porcina africana.
DE60236943D1 (de) Induzierte immunantwort gegen den katzen-immunschwäche-virus
FR2829498B1 (fr) Igf-1 comme adjuvant de vaccin felin, notamment contre les retrovirus felins
EP1439856A4 (de) Rekombinante tollwut-vakzine und verfahren zu ihrer herstellung und verwendung
DE69521007D1 (de) Impfstoff gegen Geflügelkokzidose
TW200509964A (en) VP1 of foot-and-mouth disease virus
WO2005027844A3 (en) Dna vaccine compositions and methods of use
AU2003281917A8 (en) Vaccine against infections caused by oncoviruses such as the feline leucosis virus of cats
AU2018200081B2 (en) Avirulent, immunogenic flavivirus chimeras
RU2006118106A (ru) Вектор химерного аденовируса типа 5/типа 35

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1418941

Country of ref document: EP